Significance of the MONARCH 2 Findings for Abemaciclib in HR+/HER2- Breast Cancer

June 7, 2017

Peter Kaufman, MD, associate professor of Medicine, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, discusses the significance of the MONARCH 2 trial, which explored abemaciclib in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer who progressed on endocrine therapy during the 2017 ASCO Annual Meeting.<br /> &nbsp;

Peter Kaufman, MD, associate professor of Medicine, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, discusses the significance of the MONARCH 2 trial, which explored abemaciclib in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer who progressed on endocrine therapy during the 2017 ASCO Annual Meeting.